Mankind Pharma · NSE: MANKIND · BSE: 543904

Q1 FY25 results · Apr–Jun 2024

Mankind Pharma reported revenue from operations of ₹2,893.42 crore (up 12.2% from Q1 FY24) and net profit of ₹543.07 crore (up 9.9% from Q1 FY24) for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.

Consolidated · ₹ crore
Item	Q1 FY25	Q1 FY24	YoY	Q4 FY24	QoQ
Revenue from operations	2,893.42	2,578.62	+12.2%	2,441.10	+18.5%
Other income	100.60	58.62	+71.6%	92.13	+9.2%
Total income	2,994.02	2,637.24	+13.5%	2,533.23	+18.2%
Profit before share of associates & JVs and tax	663.71	619.74	+7.1%	569.16	+16.6%
Share of profit/(loss) of associates & JVs	3.91	4.73		2.41
Net profit for the period	543.07	494.19	+9.9%	476.59	+13.9%
Attributable to shareholders of the company	536.49	—	—	471.24	+13.8%
EPS, basic (₹)	13.39	12.15	+10.2%	11.76	+13.9%
Net margin (%)	18.8	19.2		19.5

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q1 FY25	Q1 FY24	YoY	Q4 FY24	QoQ
Revenue from operations	2,403.26	2,300.21	+4.5%	2,152.69	+11.6%
Other income	94.83	57.44	+65.1%	83.85	+13.1%
Total income	2,498.09	2,357.65	+6.0%	2,236.54	+11.7%
Profit before tax	577.37	526.39	+9.7%	544.86	+6.0%
Net profit for the period	513.49	409.28	+25.5%	454.17	+13.1%
EPS, basic (₹)	12.82	10.22	+25.4%	11.34	+13.1%
Net margin (%)	21.4	17.8		21.1

Consolidated

Filed with BSE: 22 Aug 2024, 10:54 IST
Board meeting: 31 Jul 2024
Period: 01 Apr 2024 to 30 Jun 2024
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 22 Aug 2024, 10:54 IST
Board meeting: 31 Jul 2024
Period: 01 Apr 2024 to 30 Jun 2024
Review status: Unaudited
Source: XBRL filing on BSE